← All stocks

Inhibrx Biosciences, Inc.

INBX Net buying

CIK 0002007919 #2266 in the set updated 22 Sep 2026

Bought (120 mo)

$15.34M

out of their own pocket, the only kind of buying there is

Sold (120 mo)

$11.57M

$0.00 on a plan · $0.00 straight out of an exercise

Sold at will

$11.57M

8 of 8 sales

Net

+$3.77M

+$3.77M against sales at will

By person

8 insiders · 46 transactions

238×

Mark P. Lappe holds 238 times base salary in stock. $165.60M of shares against $695.25K in salary for 2025.

Salary from the company's own proxy. The shares are what Mark P. Lappe last reported holding, valued at $100.00, the price Common Stock was last bought or sold at on the open market here, on 16 Sep 2026.

Insider

Role

Bought

Sold

Net

Holding

Of company

Worth

Change

VIKING GLOBAL INVESTORS LP entity

10% owner

—

$11.29M (3)

−$11.29M

102,864

0.6989%

$10.29M

−77.3%

Kayyem Jon Faiz

Director

$8.52M (13)

—

+$8.52M

1,488,406

10.11%

$148.84M

+254.9%

Lappe Mark

Chief Executive Officer

$5.06M (17)

—

+$5.06M

1,655,961

11.25%

$165.60M

+134.7%

FORSYTH DOUGLAS

Director

$1.32M (3)

—

+$1.32M

451,628

3.07%

$45.16M

+101.1%

Vuori Kristiina MD

Director

$299.96K (4)

—

+$299.96K

20,443

0.1389%

$2.04M

—

MANHARD KIMBERLY

Director

$139.80K (1)

$279.01K (5)

−$139.21K

17,500

0.1189%

$1.75M

+75.0%

Inhibrx, Inc. entity

10% owner

—

1,157,926

7.87%

$115.79M

−92.0%

Eckelman Brendan P.

Chief Scientific Officer

—

40,000

0.2718%

$4.00M

—

Individual transactions

Nothing of that kind in this period.

What was left out

Form 4 filings counted 42

Amendments (4/A) skipped 4

Filings about a different issuer 0

Unreadable filings 0

Joint filings 1

Sales on a Rule 10b5-1 plan 0

Sales straight out of an exercise 0

Sales at will 8

Transactions with no price 0

Shares from compensation/vesting 16,810,630

History held since 30 May 2024